Septerna Reports Q4 Revenue of $24.12M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 09 2026
0mins
Should l Buy SEPN?
Reports Q4 revenue $24.12M, consensus $15.56M. "We made significant strides advancing our pipeline in the past year, and 2026 has already delivered a meaningful milestone with positive Phase 1 results for SEP-631," said Jeffrey Finer, chief executive officer and co-founder of Septerna. "These results demonstrate clinical proof-of-mechanism and validate the ability of our Native Complex Platform to uncover novel mechanisms of action and rapidly generate differentiated oral small molecules for historically challenging GPCRs. With SEP-479 approaching Phase 1 initiation in the coming months, SEP-631 poised for Phase 2 development in the second half of the year, and additional programs progressing behind them, we believe 2026 will be a year of strong progress for Septerna and for the patients we are committed to serving."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SEPN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SEPN
Wall Street analysts forecast SEPN stock price to rise
8 Analyst Rating
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 25.140
Low
25.00
Averages
33.14
High
43.00
Current: 25.140
Low
25.00
Averages
33.14
High
43.00
About SEPN
Septerna, Inc. is a clinical-stage biotechnology company. The Company is developing G protein-coupled receptor (GPCR) oral small-molecule drug discovery powered by its proprietary Native Complex Platform. Its pipeline of product candidates is focused on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. Its industrial-scale Native Complex Platform is designed to target certain GPCRs for the first time, uncover novel binding pockets for validated receptors, and pursue a wide spectrum of pharmacologies, including agonists, antagonists, and allosteric modulators, to achieve desired therapeutic effects. It is advancing a deep portfolio of oral small molecule GPCR-targeted programs with novel mechanistic approaches to treat diseases across multiple therapeutic areas for patients with unmet needs. It is focused on therapeutic areas, such as neurology, women’s health, cardiovascular, and respiratory disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Septerna, Inc. Q4 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q4 GAAP EPS of -$0.24, beating expectations by $0.02, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company achieved Q4 revenue of $24.1 million, soaring 11950% year-over-year and exceeding market expectations by $8.54 million, demonstrating robust demand and rapid growth potential for its products or services.
- Positive Future Outlook: With the Phase 1 readout of SEP-631 approaching, Septerna anticipates a key market driver in 2026, which could further boost the company's stock price and market recognition.
- Quant Rating Improvement: Seeking Alpha's quant rating on Septerna, Inc. reflects growing market confidence in its future performance, indicating investor recognition of the company's strategic direction and growth potential.
See More
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
- Clinical Trial Success: Septerna's SEP-631 demonstrated good tolerability and pharmacokinetic characteristics in its Phase 1 clinical trial for mast cell-driven diseases, supporting once-daily oral dosing with a half-life of 24 hours, indicating its potential for treating chronic spontaneous urticaria and other conditions.
- Efficacy Validation: At a dose of 10 mg, SEP-631 showed significant suppression of skin wheal formation, with nearly complete inhibition observed at 90 mg and 200 mg doses, demonstrating a dose-dependent response that further validates its application in mast cell-driven diseases.
- Follow-Up Research Plans: Based on the positive Phase 1 results, Septerna plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2023, aiming to evaluate the efficacy of SEP-631 in adult patients who remain symptomatic despite treatment with second-generation antihistamines.
- Multiple Indication Exploration: In addition to chronic spontaneous urticaria, Septerna is also exploring the efficacy of SEP-631 in other mast cell-driven diseases, including atopic dermatitis, interstitial cystitis, migraine, and asthma, showcasing its broad market potential.
See More
Positive Phase 1 Results for SEP-631 in Chronic Urticaria
- Successful Clinical Trial: SEP-631 demonstrated favorable tolerability in a Phase 1 trial with healthy volunteers, showing no severe adverse events and a safety profile comparable to placebo, indicating its potential as an oral treatment option.
- Dose-Dependent Inhibition: Complete inhibition of icatibant-induced skin wheal formation was observed at a dose as low as 10 mg, with stronger suppression at higher doses, highlighting its effectiveness in treating mast cell-driven diseases.
- Phase 2 Development Plan: The company plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2026, aiming to evaluate the efficacy of SEP-631 in patients with moderate-to-severe symptoms, thereby expanding its market application.
- Exploration of Multiple Indications: Beyond urticaria, Septerna is assessing the treatment potential of SEP-631 in other mast cell-driven diseases, including atopic dermatitis and asthma, showcasing the broad applicability of its product.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
See More
Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance
- Executive Appointment: Septerna has appointed Mark A. Wilson as Chief Legal Officer, leveraging his over 25 years of experience in intellectual property and corporate law to enhance the company's governance framework and maximize the value of its proprietary Native Complex Platform™.
- Strategic Importance: Wilson's previous role at Nektar Therapeutics, where he led global development and commercialization collaborations, equips him to effectively execute Septerna's long-term drug development strategy.
- Industry Context: As a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, Wilson's expertise will further drive innovation and development in this critical area.
- Talent Acquisition: With a Bachelor of Science in Pharmacy and a Juris Doctor degree, and being registered with the U.S. Patent and Trademark Office, Wilson's addition will enhance Septerna's legal and intellectual property management capabilities.
See More
Septerna, Inc. Q4 Earnings Exceed Expectations
- Strong Earnings Report: Septerna, Inc. reported a Q4 GAAP EPS of -$0.24, beating expectations by $0.02, indicating an improvement in financial performance despite still being in a loss position.
- Significant Revenue Growth: The company achieved Q4 revenue of $24.1 million, soaring 11950% year-over-year and exceeding market expectations by $8.54 million, demonstrating robust demand and rapid growth potential for its products or services.
- Positive Future Outlook: With the Phase 1 readout of SEP-631 approaching, Septerna anticipates a key market driver in 2026, which could further boost the company's stock price and market recognition.
- Quant Rating Improvement: Seeking Alpha's quant rating on Septerna, Inc. reflects growing market confidence in its future performance, indicating investor recognition of the company's strategic direction and growth potential.
See More
Septerna Reports Positive Phase 1 Results for SEP-631 in Mast Cell-Driven Diseases
- Clinical Trial Success: Septerna's SEP-631 demonstrated good tolerability and pharmacokinetic characteristics in its Phase 1 clinical trial for mast cell-driven diseases, supporting once-daily oral dosing with a half-life of 24 hours, indicating its potential for treating chronic spontaneous urticaria and other conditions.
- Efficacy Validation: At a dose of 10 mg, SEP-631 showed significant suppression of skin wheal formation, with nearly complete inhibition observed at 90 mg and 200 mg doses, demonstrating a dose-dependent response that further validates its application in mast cell-driven diseases.
- Follow-Up Research Plans: Based on the positive Phase 1 results, Septerna plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2023, aiming to evaluate the efficacy of SEP-631 in adult patients who remain symptomatic despite treatment with second-generation antihistamines.
- Multiple Indication Exploration: In addition to chronic spontaneous urticaria, Septerna is also exploring the efficacy of SEP-631 in other mast cell-driven diseases, including atopic dermatitis, interstitial cystitis, migraine, and asthma, showcasing its broad market potential.
See More
Positive Phase 1 Results for SEP-631 in Chronic Urticaria
- Successful Clinical Trial: SEP-631 demonstrated favorable tolerability in a Phase 1 trial with healthy volunteers, showing no severe adverse events and a safety profile comparable to placebo, indicating its potential as an oral treatment option.
- Dose-Dependent Inhibition: Complete inhibition of icatibant-induced skin wheal formation was observed at a dose as low as 10 mg, with stronger suppression at higher doses, highlighting its effectiveness in treating mast cell-driven diseases.
- Phase 2 Development Plan: The company plans to initiate a Phase 2b clinical trial for chronic spontaneous urticaria in the second half of 2026, aiming to evaluate the efficacy of SEP-631 in patients with moderate-to-severe symptoms, thereby expanding its market application.
- Exploration of Multiple Indications: Beyond urticaria, Septerna is assessing the treatment potential of SEP-631 in other mast cell-driven diseases, including atopic dermatitis and asthma, showcasing the broad applicability of its product.
See More
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
- Market Surge: U.S. stocks rose significantly on Monday, with the Dow Jones index gaining over 350 points, indicating strong investor confidence and potentially attracting more capital into the market.
- Peakstone Realty Trust Price Surge: Shares of Peakstone Realty Trust soared 32.5% to $20.70 on Friday, reflecting positive market sentiment regarding the company's future prospects and the anticipated benefits of the acquisition.
- Acquisition Announcement: Brookfield announced plans to acquire Peakstone Realty Trust in a $1.2 billion all-cash deal, which not only enhances Brookfield's asset portfolio but also signals its strategic intent to expand further in the real estate sector.
- Positive Market Reaction: Following the acquisition news, Peakstone Realty Trust's stock price surged, indicating strong investor confidence in the deal and potentially attracting additional investment into the company.
See More
Aktis Oncology Launches $200 Million IPO with $100 Million Investment from Eli Lilly
- IPO Market Recovery: Aktis Oncology launched a $200 million IPO on Monday, indicating a resurgence in the biotech IPO market after a period of uneven performance, and is set to be the first significant IPO of 2026.
- Increased Financing Size: Just two days after the IPO launch, Aktis upsized the deal by 50%, which not only reflects growing investor confidence in its prospects but also indicates a rising interest in the biotech sector.
- Strategic Partnership Support: Aktis disclosed a $100 million investment from partner Eli Lilly, which will provide robust support for the company's R&D and market expansion, further strengthening its position in the competitive biotech landscape.
- Optimistic Market Outlook: As the first major biotech IPO of 2026, Aktis's success could attract more investor attention to the biotech sector, potentially driving recovery and growth across the industry.
See More
Septerna Appoints Mark A. Wilson as Chief Legal Officer to Enhance Governance
- Executive Appointment: Septerna has appointed Mark A. Wilson as Chief Legal Officer, leveraging his over 25 years of experience in intellectual property and corporate law to enhance the company's governance framework and maximize the value of its proprietary Native Complex Platform™.
- Strategic Importance: Wilson's previous role at Nektar Therapeutics, where he led global development and commercialization collaborations, equips him to effectively execute Septerna's long-term drug development strategy.
- Industry Context: As a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery, Wilson's expertise will further drive innovation and development in this critical area.
- Talent Acquisition: With a Bachelor of Science in Pharmacy and a Juris Doctor degree, and being registered with the U.S. Patent and Trademark Office, Wilson's addition will enhance Septerna's legal and intellectual property management capabilities.
See More
